m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05646
 [1]
m6A modification GAS5 GAS5 FTO Demethylation : m6A sites Direct Inhibition Non-coding RNA GAS5 BRD4  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
m6A Target Growth arrest specific 5 (GAS5)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Growth arrest specific 5 (GAS5) LncRNA View Details
Regulated Target Bromodomain-containing protein 4 (BRD4) View Details
Crosstalk Relationship m6A  →  ncRNA Inhibition
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary LncRNA Growth arrest specific 5 (GAS5) regulated by FTO-mediated m6A demethylation promotes autophagic cell death in NSCLC by targeting UPF1/Bromodomain-containing protein 4 (BRD4) axis.
Responsed Disease Non-small cell lung cancer ICD-11: 2C25.Y
 Disease Info 
Cell Process mRNA stability
Cell autophagy
In-vitro Model
 BEAS-2B Normal Homo sapiens CVCL_0168
NCI-H322 Minimally invasive lung adenocarcinoma Homo sapiens CVCL_1556
NCI-H650 Lung adenocarcinoma Homo sapiens CVCL_1575
HCC827 Lung adenocarcinoma Homo sapiens CVCL_2063
NCI-H1299 Lung large cell carcinoma Homo sapiens CVCL_0060
NCI-H358 Minimally invasive lung adenocarcinoma Homo sapiens CVCL_1559
NCI-H838 Lung adenocarcinoma Homo sapiens CVCL_1594
NCI-H23 Lung adenocarcinoma Homo sapiens CVCL_1547
In-vivo Model Animal experiments were approved by the Hainan Affiliated Hospital of Hainan Medical University. Male BALB/c mice (Vital River, Beijing, China) were subcutaneously injected with H322 cells (1 × 106) transfected with ov-NC, ov-FTO, ov-GAS5 or ov-FTO + ov-GAS5 (n = 5/group). Tumor volume was measured every 7 days, and mice were sacrificed and the tumor tissues were removed for weighting and analyzing after 35 days. Also, tumor tissues were prepared into paraffin sections to carry out Ki67 immunohistochemistry (IHC) staining using SP Kit (Solarbio, Beijing, China) and TUNEL staining using Colorimetric TUNEL Apoptosis Assay Kit (Beyotime) basing on kit instructions.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Bromodomain-containing protein 4 (BRD4) 60 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name CPI-0610 Phase 3 [2]
MOA Modulator
Activity IC50 = 39 nM
External Link
CID: 57389999
TTD: D01LVE
 Compound Name PLX2853 Phase 1/2 [3]
MOA Inhibitor
External Link
TTD: D07GHA
 Compound Name RVX-208 Phase 1/2 [2]
MOA Modulator
External Link
CID: 24871506
TTD: D0N7WW
 Compound Name INCB57643 Phase 1/2 [3]
MOA Inhibitor
External Link
TTD: D0P7FM
 Compound Name OTX-015 Phase 1/2 [2]
Synonyms
MK 8628
    Click to Show/Hide
MOA Modulator
Activity Ki = 5.7 nM
External Link
CID: 9936746
TTD: D02YNI
DrugBank: DB15189
 Compound Name TEN010 Phase 1 [2]
MOA Modulator
External Link
TTD: D0B5PK
 Compound Name AZD5153 Phase 1 [3]
Synonyms
RSMYFSPOTCDHHJ-GOSISDBHSA-N; AZD-5153; 1869912-39-9; UNII-C7C7U6YEAO; C7C7U6YEAO; SCHEMBL17477306; MolPort-044-561-768; AZD 5153 [WHO-DD]; AZD 5153; EX-A1317; BCP20057; ZINC575441177; AKOS030627661; SB18713; AS-35242; J3.544.368A; (3r)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one; XNH; 2-Piperazinone, 4-(2-(4-(1-(3-methoxy-1,2,4-triazolo(4,3-b)pyridazin-6-yl)-4-piperidinyl)phenoxy)ethyl)-1,3-dimethyl-, (3R)-; (R)-4-(2-(4-(1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)pipe
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 5 nM
External Link
CID: 118693659
TTD: D0PH9I
 Compound Name GSK525762 Phase 1 [2]
Synonyms
GSK-525762
    Click to Show/Hide
MOA Modulator
Activity Ki = 23 nM
External Link
CID: 46943432
TTD: D07OFM
 Compound Name ABBV-744 Phase 1 [3]
Synonyms
OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 1.6 nM
External Link
CID: 132010322
TTD: D05ICT
 Compound Name (+)-JQ1 Phase 1 [4]
Synonyms
1268524-70-4; (+)-JQ-1; JQ1 compound; JQ-1; UNII-1MRH0IMX0W; (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; (S)-JQ1; 1MRH0IMX0W; JQ1; CHEMBL1957266; AK109409; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate; (S)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 5.3 nM
External Link
CID: 46907787
TTD: D0ZW4W
 Compound Name PMID26924192-Compound-23 Patented [5]
MOA Inhibitor
External Link
CID: 118437924
TTD: D00MXR
 Compound Name Aminocyclopentenone compound 1 Patented [5]
Synonyms
PMID26924192-Compound-93
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
CID: 117928501
TTD: D04HTM
 Compound Name Pyrazole and thiophene derivative 4 Patented [5]
Synonyms
PMID26924192-Compound-92
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 118487470
TTD: D05LTB
 Compound Name Benzothiazepine analog 12 Patented [5]
Synonyms
PMID26924192-Compound-99
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 50 nM
External Link
CID: 118080061
TTD: D07CSE
 Compound Name PMID26924192-Compound-20 Patented [5]
MOA Inhibitor
External Link
CID: 118437927
TTD: D07IYX
 Compound Name PMID26924192-Compound-24 Patented [5]
MOA Inhibitor
External Link
CID: 91971319
TTD: D08BCK
 Compound Name Aminocyclopentenone compound 2 Patented [5]
Synonyms
PMID26924192-Compound-94
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
CID: 117928438
TTD: D08JHQ
 Compound Name Pyrrolo-pyrrolone derivative 3 Patented [5]
Synonyms
PMID26924192-Compound-36
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 11 nM
External Link
CID: 122553422
TTD: D09FVR
 Compound Name Aminocyclopentenone compound 5 Patented [5]
Synonyms
PMID26924192-Compound-97
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
CID: 117928680
TTD: D09QSH
 Compound Name Aminocyclopentenone compound 6 Patented [5]
Synonyms
PMID26924192-Compound-98
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
TTD: D0AU3O
 Compound Name PMID26924192-Compound-22 Patented [5]
MOA Inhibitor
External Link
CID: 118437971
TTD: D0C9RQ
 Compound Name PMID26924192-Compound-31 Patented [5]
MOA Inhibitor
External Link
CID: 124182114
TTD: D0CB8D
 Compound Name Pyrazole and thiophene derivative 2 Patented [5]
Synonyms
PMID26924192-Compound-90
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 118487503
TTD: D0EN4B
 Compound Name PMID26924192-Compound-25 Patented [5]
MOA Inhibitor
External Link
CID: 118437925
TTD: D0FN6F
 Compound Name Pyrrolo-pyrrolone derivative 4 Patented [5]
Synonyms
PMID26924192-Compound-37
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 11 nM
External Link
CID: 118095161
TTD: D0HO8V
 Compound Name Pyrazole and thiophene derivative 3 Patented [5]
Synonyms
PMID26924192-Compound-91
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 136991243
TTD: D0J4QG
 Compound Name Aminocyclopentenone compound 3 Patented [5]
Synonyms
PMID26924192-Compound-95
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
CID: 117928427
TTD: D0KF8C
 Compound Name Aminocyclopentenone compound 4 Patented [5]
Synonyms
PMID26924192-Compound-96
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
CID: 117928624
TTD: D0N6JZ
 Compound Name Pyrrolo-pyrrolone derivative 2 Patented [5]
Synonyms
PMID26924192-Compound-35
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 11 nM
External Link
CID: 118095207
TTD: D0PE1R
 Compound Name Benzothiazepine analog 11 Patented [5]
Synonyms
PMID26924192-Compound-101
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 50 nM
External Link
CID: 118080527
TTD: D0S5ID
 Compound Name Pyrazole and thiophene derivative 1 Patented [5]
Synonyms
PMID26924192-Compound-89
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 92045047
TTD: D0SQ0F
 Compound Name PMID26924192-Compound-21 Patented [5]
MOA Inhibitor
External Link
CID: 118437931
TTD: D0XM8B
 Compound Name Pyrrolo-pyrrolone derivative 5 Patented [5]
Synonyms
PMID26924192-Compound-38
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 11 nM
External Link
CID: 118095173
TTD: D0XR9Y
 Compound Name Benzothiazepine analog 10 Patented [5]
Synonyms
PMID26924192-Compound-100
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 50 nM
External Link
CID: 118079255
TTD: D0Y7YC
 Compound Name PMID26924192-Compound-30 Patented [5]
MOA Inhibitor
External Link
CID: 124182286
TTD: D0L7SK
 Compound Name PMID26924192-Compound-32 Patented [5]
MOA Inhibitor
External Link
CID: 91864635
TTD: D0SB3H
 Compound Name PMID26924192-Compound-33 Patented [5]
MOA Inhibitor
External Link
CID: 124182231
TTD: D0VB3P
 Compound Name Pyrrolo-pyrrolone derivative 1 Patented [5]
Synonyms
PMID26924192-Compound-34
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 11 nM
External Link
CID: 122553486
TTD: D0YM3G
 Compound Name PMID26924192-Compound-104 Patented [5]
MOA Inhibitor
External Link
CID: 118548317
TTD: D03NWT
 Compound Name PMID26924192-Compound-102 Patented [5]
MOA Inhibitor
Activity IC50 = 41 nM
External Link
CID: 102004282
TTD: D03RPJ
 Compound Name PMID26924192-Compound-103 Patented [5]
MOA Inhibitor
External Link
CID: 118542373
TTD: D05XXS
 Compound Name PMID26924192-Compound-105 Patented [5]
MOA Inhibitor
External Link
CID: 118548311
TTD: D0NN4U
 Compound Name XD1 Investigative [6]
Synonyms
colchicein; colchiceine; NSC33411
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 234105
TTD: D01DMN
 Compound Name PMID25703523C7d Investigative [7]
Synonyms
43U; GTPL8304
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 90684387
TTD: D01EVE
 Compound Name isoxazole azepine compound 3 Investigative [8]
MOA Inhibitor
Activity IC50 = 26 nM
External Link
CID: 57345400
TTD: D01YSN
 Compound Name PFI-1 Investigative [9]
Synonyms
QCR-192; HY-16586; PF-6405761
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 220 nM
External Link
CID: 71271629
TTD: D03LNF
 Compound Name MS436 Investigative [10]
MOA Inhibitor
Activity Ki < 85 nM
External Link
CID: 135566899
TTD: D09HBR
 Compound Name CPI-203 Investigative [11]
Synonyms
CPI203; CPI 203
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 92 nM
External Link
CID: 71291068
TTD: D0C2JS
 Compound Name BzT-7 Investigative [12]
Synonyms
CHEMBL1958337; 8-Chloro-1,4-Dimethyl-6-Phenyl-4h-[1,2,4]triazolo[4,3-A][1,3,4]benzotriazepine; 3u5l; GTPL7515; SCHEMBL11468349; UYIVCPRWMLOCSB-UHFFFAOYSA-N; BDBM50365263; 8-chloro-1,4-dimethyl-6-phenyl-[1,2,4]triazolo[4,3-a][1,3,4]benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a)(1,3,4)benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a)(1,3,4 )benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a) (1,3,4)benzotriazepine
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 20350618
TTD: D0M5DB
 Compound Name PMID23517011C9 Investigative [13]
Synonyms
GTPL7517; BDBM50430836
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 371.54 nM
External Link
CID: 71624782
TTD: D0O2RX
 Compound Name MS417 Investigative [14]
Synonyms
Methyl [(6s)-4-(4-Chlorophenyl)-2,3,9-Trimethyl-6h-Thieno[3,2-F][1,2,4]triazolo[4,3-A][1,4]diazepin-6-Yl]acetate; 916489-36-6; GGRCIHACOIMRKY-HNNXBMFYSA-N; 0S6; 4f3i; US9125915, compound 6; GTPL7512; CHEMBL3769755; SCHEMBL12228301; CHEBI:83406; BDBM179283; MS-417; ZINC95921068; HY-111139; CS-0034388; Methyl 2-((6S,Z)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; methyl (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 16.7 nM
External Link
CID: 59190723
TTD: D0T3YY
 Compound Name PMID25408830C3 Investigative [15]
Synonyms
GSK-5959; 901245-65-6; GSK5959; GSK 5959; 4uye; GTPL7811; MolPort-004-921-361; HMS1821D17; EX-A2263; BCP16039; ZINC8594565; BDBM50032912; AKOS000481208; MCULE-6727694163; CS-4867; NCGC00107508-01; HY-18665; C301-5895; 9F9; N-[
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3162.28 nM
External Link
CID: 15990224
TTD: D03BTJ
 Compound Name PMID25408830C1 Investigative [15]
Synonyms
BAS 08314227; 4uyd; AC1LLXEX; ChemDiv2_002770; MLS000100042; GTPL7809; MolPort-001-912-793; HMS2483G18; HMS1376N20; ZINC812404; BDBM50032913; AKOS001788033; MCULE-4972680634; SMR000081748; V1T
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 79432.82 nM
External Link
CID: 1091852
TTD: D09ZPM
 Compound Name PMID21851057C4d Investigative [16]
Synonyms
GTPL7516; BDBM50353596
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4786.3 nM
External Link
CID: 54669868
TTD: D0H3TC
 Compound Name PMID25408830C2 Investigative [15]
Synonyms
AC1LNW3E; MLS000663364; GTPL7810; MolPort-002-097-893; HMS2628P17; HMS3438L21; ZINC1063855; BDBM50032921; STL431755; AKOS000445117; MCULE-6603148725; CCG-129099; SMR000300929; SR-01000295962; SR-01000295962-1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2500 nM
External Link
CID: 1253361
TTD: D0J6XI
 Compound Name GW841819X Investigative [17]
Synonyms
KB-75882
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 15.5 nM
External Link
CID: 13953710
TTD: D03LIP
 Compound Name PMID24000170C36 Investigative [18]
Synonyms
GTPL7521
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 75124304
TTD: D0C2XT
 Compound Name PMID24000170C38 Investigative [18]
Synonyms
GTPL7522
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 75124305
TTD: D0Q2GK
 Compound Name I-BET151 Investigative [19]
Synonyms
GSK1210151A
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 9 nM
External Link
CID: 52912189
TTD: D0WU1S
 Compound Name XD14 Investigative [6]
Synonyms
1370888-71-3; XD 14; 4-acetyl-N-[5-(diethylsulfamoyl)-2-hydroxyphenyl]-3-ethyl-5-methyl-1H-pyrrole-2-carboxamide; CHEMBL3787231; 4-acetyl-N-(5-(N,N-diethylsulfamoyl)-2-hydroxyphenyl)-3-ethyl-5-methyl-1H-pyrrole-2-carboxamide; 4lyw; GTPL7524; SCHEMBL16181763; AOB6049; MolPort-010-365-022; XD-14; EX-A1864; ZINC59367920; BDBM50158909; AKOS025293503; NE41584; MCULE-3472066147; Z606699744
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 52670832
TTD: D07FGY
2C25: Lung cancer 52 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Adagrasib Approved [20]
Synonyms
2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-
    Click to Show/Hide
External Link
CID: 138611145
TTD: DUQV41
 Compound Name Amivantamab Approved [21]
External Link
TTD: DQ5X1Z
 Compound Name Mobocertinib Approved [22]
Synonyms
1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate
    Click to Show/Hide
External Link
CID: 118607832
TTD: DI4HA7
 Compound Name Sugemalimab Approved in China [23]
External Link
TTD: DDZ48Y
 Compound Name Sacituzumab govitecan Approved [24]
Synonyms
1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6
    Click to Show/Hide
External Link
CID: 91668186
TTD: D8LAE2
 Compound Name Atezolizumab Approved [25]
External Link
TTD: D0YM2K
 Compound Name Tepotinib Approved [26]
Synonyms
1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo
    Click to Show/Hide
External Link
CID: 25171648
TTD: D0R8QG
DrugBank: DB15133
 Compound Name Sotorasib Approved [27]
Synonyms
AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-
    Click to Show/Hide
External Link
CID: 137278711
TTD: D0R7LD
DrugBank: DB15569
 Compound Name Entrectinib Approved [28]
Synonyms
1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
    Click to Show/Hide
External Link
CID: 25141092
TTD: D0O0LS
DrugBank: DB11986
 Compound Name Repotrectinib Approved [29]
Synonyms
FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778
    Click to Show/Hide
External Link
CID: 135565923
TTD: D05NFR
 Compound Name MYL-1402O Phase 3 [30]
Synonyms
bevacizumab biosimilar
    Click to Show/Hide
External Link
TTD: DYH3Q6
 Compound Name AB154 Phase 3 [31]
Synonyms
Domvanalimab
    Click to Show/Hide
External Link
TTD: DT1FS0
 Compound Name Datopotamab deruxtecan Phase 3 [32]
External Link
TTD: DP41HV
 Compound Name CS1001 Phase 3 [33]
External Link
TTD: D3MP1S
 Compound Name JDQ443 Phase 3 [34]
Synonyms
(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580
    Click to Show/Hide
External Link
CID: 156501355
TTD: D37IQM
 Compound Name TRS003 Phase 3 [35]
External Link
TTD: D2KVG4
 Compound Name Tusamitamab ravtansine Phase 3 [36]
Synonyms
SAR408701
    Click to Show/Hide
External Link
TTD: D2D6NJ
 Compound Name RG6058 Phase 3 [37]
Synonyms
Tiragolumab
    Click to Show/Hide
External Link
TTD: D0L4VD
 Compound Name GSK4069889 Phase 2 [38]
Synonyms
TSR-022
    Click to Show/Hide
External Link
TTD: DZW53X
 Compound Name APL-101 Phase 2 [39]
Synonyms
Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine
    Click to Show/Hide
External Link
CID: 72202701
TTD: DV3Y7F
 Compound Name SGN-LIV1A Phase 2 [40]
Synonyms
Ladiratuzumab Vedotin
    Click to Show/Hide
External Link
TTD: DS6B1L
 Compound Name BNT116 Phase 2 [41]
External Link
TTD: DR39GZ
 Compound Name AZD7789 Phase 2 [42]
External Link
TTD: DNI7E3
 Compound Name L-DOS47 Phase 1/2 [43]
External Link
TTD: DN3Z5D
 Compound Name NC318 Phase 2 [44]
External Link
TTD: D9UZ5Q
 Compound Name Vorolanib Phase 2 [45]
Synonyms
UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-
    Click to Show/Hide
External Link
CID: 59215954
TTD: D8AG3S
DrugBank: DB15247
 Compound Name Xofigo Phase 2 [46]
External Link
TTD: D6B7FP
 Compound Name Bintrafusp alfa Phase 2 [47]
External Link
TTD: D5J3BL
 Compound Name Voyager-V1 Phase 2 [48]
Synonyms
VSV-IFNBeta-NIS
    Click to Show/Hide
External Link
TTD: D4AGB6
 Compound Name AB-106 Phase 2 [49]
Synonyms
DS6051b; GTPL11198; AB106
    Click to Show/Hide
External Link
CID: 154699459
TTD: D2KV8B
 Compound Name RO-5126766 Phase 2 [50]
Synonyms
VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche
    Click to Show/Hide
External Link
CID: 16719221
TTD: D0M6BD
DrugBank: DB15254
 Compound Name TC-210 Phase 1/2 [51]
External Link
TTD: DX6O9V
 Compound Name EMB-01 Phase 1/2 [52]
External Link
TTD: DWQ6J1
 Compound Name NM21-1480 Phase 1/2 [53]
External Link
TTD: DUVH60
 Compound Name MRx0518 Phase 1/2 [54]
External Link
TTD: DP4J2K
 Compound Name DZD9008 Phase 1/2 [55]
External Link
TTD: DM8Y2N
 Compound Name BGB-A425 Phase 1/2 [56]
External Link
TTD: D7UIZ1
 Compound Name Rilvegostomig Phase 1/2 [57]
Synonyms
AZD2936
    Click to Show/Hide
External Link
TTD: D4RMC9
 Compound Name IK-007 Phase 1/2 [58]
Synonyms
grapiprant
    Click to Show/Hide
External Link
TTD: D1KES8
 Compound Name IBI318 Phase 1 [59]
External Link
TTD: DX30BA
 Compound Name GEN-011 Phase 1 [60]
External Link
TTD: DR1YQ7
 Compound Name ENV-105 Phase 1 [61]
Synonyms
Carotuximab
    Click to Show/Hide
External Link
TTD: DQ8K3R
 Compound Name AMG 160 Phase 1 [62]
External Link
TTD: DOY4E6
 Compound Name ADP-A2M10 Phase 1 [63]
External Link
TTD: DM38KC
 Compound Name MEDI5752 Phase 1 [64]
External Link
TTD: D7L1MP
 Compound Name PF-07104091 Phase 1 [65]
External Link
TTD: D5TH2B
 Compound Name PF-06936308 Phase 1 [66]
External Link
TTD: D2LUK7
 Compound Name GEM3PSCA Phase 1 [67]
External Link
TTD: D1L7DE
 Compound Name PF-07257876 Phase 1 [68]
External Link
TTD: D1A7OP
 Compound Name Cosibelimab Phase 1 [69]
Synonyms
CK-301/TG-1501
    Click to Show/Hide
External Link
TTD: D17URP
 Compound Name Gemcitabine Approved [70]
External Link
CID: 60750
TTD: D0AJ3K
DrugBank: DB00441
 Compound Name SMI-4a Investigative [71]
Synonyms
438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione
    Click to Show/Hide
External Link
CID: 1361334
TTD: DAJ3D2
References
Ref 1 LncRNA GAS5 regulated by FTO-mediated m6A demethylation promotes autophagic cell death in NSCLC by targeting UPF1/BRD4 axis. Mol Cell Biochem. 2024 Mar;479(3):553-566. doi: 10.1007/s11010-023-04748-6. Epub 2023 Apr 29.
Ref 2 Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014 May;13(5):337-56. doi: 10.1038/nrd4286. Epub 2014 Apr 22.
Ref 3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 4 Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73.
Ref 5 BET inhibitors in cancer therapeutics: a patent review. Expert Opin Ther Pat. 2016;26(4):505-22. doi: 10.1517/13543776.2016.1159299. Epub 2016 Mar 15.
Ref 6 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9. doi: 10.1002/anie.201307652. Epub 2013 Nov 24.
Ref 7 9H-purine scaffold reveals induced-fit pocket plasticity of the BRD9 bromodomain. J Med Chem. 2015 Mar 26;58(6):2718-36.
Ref 8 Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors. ACS Med Chem Lett. 2013 Jul 16;4(9):835-40. doi: 10.1021/ml4001485. eCollection 2013 Sep 12.
Ref 9 Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem. 2012 Nov 26;55(22):9831-7. doi: 10.1021/jm3010515. Epub 2012 Nov 8.
Ref 10 Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. J Med Chem. 2013 Nov 27;56(22):9251-64. doi: 10.1021/jm401334s. Epub 2013 Nov 11.
Ref 11 BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A. 2012 May 1;109(18):6927-32.
Ref 12 Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. Bioorg Med Chem. 2012 Mar 15;20(6):1878-86.
Ref 13 Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. J Med Chem. 2013 Apr 25;56(8):3217-27.
Ref 14 Down-regulation of NF-KappaB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem. 2012 Aug 17;287(34):28840-51. doi: 10.1074/jbc.M112.359505. Epub 2012 May 29.
Ref 15 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5. doi: 10.1021/ml5002932. eCollection 2014 Nov 13.
Ref 16 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem. 2011 Oct 13;54(19):6761-70.
Ref 17 Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011 Jun 9;54(11):3827-38. doi: 10.1021/jm200108t. Epub 2011 May 13.
Ref 18 Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9. doi: 10.1002/cmdc.201300259. Epub 2013 Sep 2.
Ref 19 Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011 Oct 2;478(7370):529-33. doi: 10.1038/nature10509.
Ref 20 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 216340.
Ref 21 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761210.
Ref 22 ClinicalTrials.gov (NCT04129502) TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations. U.S. National Institutes of Health.
Ref 23 Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
Ref 24 ClinicalTrials.gov (NCT05089734) Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy. U.S.National Institutes of Health.
Ref 25 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
Ref 26 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
Ref 27 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 214665.
Ref 28 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
Ref 29 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 218213
Ref 30 ClinicalTrials.gov (NCT04633564) Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin?, in the First-line Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer. U.S.National Institutes of Health.
Ref 31 ClinicalTrials.gov (NCT04736173) Study to Evaluate Monotherapy Compared to Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 32 ClinicalTrials.gov (NCT05555732) A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07). U.S.National Institutes of Health.
Ref 33 ClinicalTrials.gov (NCT03728556) A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 34 ClinicalTrials.gov (NCT05132075) A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer. U.S.National Institutes of Health.
Ref 35 ClinicalTrials.gov (NCT04416035) A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in Subjects With Advanced Nonsquamous NSCLC. U.S.National Institutes of Health.
Ref 36 ClinicalTrials.gov (NCT05245071) Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA. U.S.National Institutes of Health.
Ref 37 ClinicalTrials.gov (NCT04294810) A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01). U.S. National Institutes of Health.
Ref 38 ClinicalTrials.gov (NCT04655976) Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants (COSTAR Lung). U.S. National Institutes of Health.
Ref 39 ClinicalTrials.gov (NCT04258033) A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation. U.S. National Institutes of Health.
Ref 40 ClinicalTrials.gov (NCT04032704) A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 41 ClinicalTrials.gov (NCT05557591) A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 >=50%. U.S.National Institutes of Health.
Ref 42 ClinicalTrials.gov (NCT04931654) A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
Ref 43 ClinicalTrials.gov (NCT02340208) A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47. U.S. National Institutes of Health.
Ref 44 ClinicalTrials.gov (NCT04699123) The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 45 ClinicalTrials.gov (NCT03848611) CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).. U.S. National Institutes of Health.
Ref 46 ClinicalTrials.gov (NCT02283749) BrUOG L301: Xofigo Following Frontline-Line Chemotherapy For Patients With Non-Small Cell Lung Cancer and Bone Metastases. U.S.National Institutes of Health.
Ref 47 ClinicalTrials.gov (NCT04560686) Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 48 ClinicalTrials.gov (NCT04291105) Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients. U.S. National Institutes of Health.
Ref 49 ClinicalTrials.gov (NCT04395677) A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene. U.S. National Institutes of Health.
Ref 50 ClinicalTrials.gov (NCT04625270) A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation. U.S. National Institutes of Health.
Ref 51 ClinicalTrials.gov (NCT03907852) Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer. U.S. National Institutes of Health.
Ref 52 ClinicalTrials.gov (NCT03797391) A Dose Escalation Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors. U.S. National Institutes of Health.
Ref 53 ClinicalTrials.gov (NCT04442126) A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 54 ClinicalTrials.gov (NCT03637803) Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors. U.S. National Institutes of Health.
Ref 55 ClinicalTrials.gov (NCT03974022) Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1). U.S. National Institutes of Health.
Ref 56 ClinicalTrials.gov (NCT03744468) Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 57 ClinicalTrials.gov (NCT04995523) Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC. U.S.National Institutes of Health.
Ref 58 ClinicalTrials.gov (NCT03696212) Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma. U.S.National Institutes of Health.
Ref 59 ClinicalTrials.gov (NCT04777084) The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.. U.S. National Institutes of Health.
Ref 60 ClinicalTrials.gov (NCT04596033) TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy. U.S. National Institutes of Health.
Ref 61 ClinicalTrials.gov (NCT05401110) IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer. U.S.National Institutes of Health.
Ref 62 ClinicalTrials.gov (NCT04822298) Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 63 Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer. J Immunother Cancer. 2022 Jan;10(1):e003581.
Ref 64 ClinicalTrials.gov (NCT03819465) A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN). U.S. National Institutes of Health.
Ref 65 ClinicalTrials.gov (NCT04553133) PF-07104091 as a Single Agent and in Combination Therapy. U.S. National Institutes of Health.
Ref 66 ClinicalTrials.gov (NCT03674827) Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC. U.S. National Institutes of Health.
Ref 67 ClinicalTrials.gov (NCT03927573) Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker. U.S. National Institutes of Health.
Ref 68 ClinicalTrials.gov (NCT04881045) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS. U.S.National Institutes of Health.
Ref 69 ClinicalTrials.gov (NCT04786964) Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (CONTERNO). U.S. National Institutes of Health.
Ref 70 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 71 Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway. Onco Targets Ther. 2019 Apr 23;12:3043-3050.